brl 42810 has been researched along with Recrudescence in 68 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this multicenter, multinational, double-blind, parallel-group study, 1179 adults with a history of recurrent genital herpes were randomized 1:1 to receive either famciclovir or valacyclovir." | 9.13 | Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. ( Abudalu, M; Bodsworth, N; Hamed, K; Koltun, W; Tyring, S, 2008) |
| "To compare the clinical and virologic effects of famciclovir and valacyclovir administered as daily suppressive therapy for persons with genital herpes." | 9.12 | Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. ( Aoki, FY; Corey, L; Diaz-Mitoma, F; Sacks, S; Selke, S; Wald, A; Warren, T, 2006) |
| "Lamivudine is a nucleoside analogue with efficacy in the suppression of hepatitis B viral (HBV) replication." | 7.70 | Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up. ( Bain, VG; Davis, JE; Erb, SR; Fischer, KP; Kneteman, NM; Ma, MM; Tyrrell, DL; Yoshida, EM, 1998) |
| "Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT)." | 7.70 | Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. ( Bock, T; Böker, KH; Bruns, I; Condreay, LD; Gauthier, J; Glowienka, M; Jäckel, E; Manns, MP; Oldhafer, K; Raab, HR; Tillmann, HL; Trautwein, C, 1999) |
| "We have documented HBV recurrence in a liver transplant recipient with the emergence of a multidrug resistant HBV which caused graft loss." | 5.30 | The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. ( Bartholomeusz, AI; de Man, RA; Locarnini, SA; Niesters, HG; Zondervan, PE, 1998) |
| "In this multicenter, multinational, double-blind, parallel-group study, 1179 adults with a history of recurrent genital herpes were randomized 1:1 to receive either famciclovir or valacyclovir." | 5.13 | Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. ( Abudalu, M; Bodsworth, N; Hamed, K; Koltun, W; Tyring, S, 2008) |
| "To compare the clinical and virologic effects of famciclovir and valacyclovir administered as daily suppressive therapy for persons with genital herpes." | 5.12 | Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. ( Aoki, FY; Corey, L; Diaz-Mitoma, F; Sacks, S; Selke, S; Wald, A; Warren, T, 2006) |
| "To compare the effectiveness and safety of three oral antiviral drugs (acyclovir, famciclovir and valacyclovir) prescribed to suppress genital herpes outbreaks in non-pregnant patients." | 4.90 | Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. ( Chosidow, O; Do, G; Le Cleach, L; Lebrun-Vignes, B; Maruani, A; Ravaud, P; Trinquart, L, 2014) |
| "Efficacy of oral antiviral therapies, ie, acyclovir, valacyclovir (VACV), and famciclovir, for suppression of recurrent genital herpes was studied at different doses and regimens." | 4.84 | A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. ( Bouzamondo, A; Chosidow, O; Dupuy, A; Guillaume, JC; Lebrun-Vignes, B; Lechat, P, 2007) |
| "A literature search was performed in MEDLINE (1966-August 2003) using acyclovir, famciclovir, valacyclovir, cold sores, herpes labialis, and HSV-1 as search terms." | 4.82 | Oral antivirals for the acute treatment of recurrent herpes labialis. ( Hoehns, JD; Jensen, LA; Squires, CL, 2004) |
| "Nucleoside analogues such as lamivudine for chronic hepatitis B have an excellent safety profile while patients are on therapy but reactivation flares occur in 19-50% of patients after stopping therapy, some of whom develop liver decompensation." | 3.71 | Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. ( Guan, R; Kajiji, T; Lim, SG; Rajnakova, A; Wai, CT, 2002) |
| " Lamivudine is safe and effective in liver transplant recipients with recurrent hepatitis B virus (HBV) infection caused by wild-type virus or failure of hepatitis B immunoglobulin therapy." | 3.71 | Treatment of recurrent hepatitis B infection in liver transplant recipients. ( Terrault, NA, 2002) |
| "Lamivudine is a nucleoside analogue with efficacy in the suppression of hepatitis B viral (HBV) replication." | 3.70 | Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up. ( Bain, VG; Davis, JE; Erb, SR; Fischer, KP; Kneteman, NM; Ma, MM; Tyrrell, DL; Yoshida, EM, 1998) |
| "Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT)." | 3.70 | Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. ( Bock, T; Böker, KH; Bruns, I; Condreay, LD; Gauthier, J; Glowienka, M; Jäckel, E; Manns, MP; Oldhafer, K; Raab, HR; Tillmann, HL; Trautwein, C, 1999) |
| "For the primary infection of genital herpes, antiviral therapy with acyclovir is the gold standard." | 3.70 | Update on antiviral therapy for genital herpes infection. ( Geers, TA; Isada, CM, 2000) |
| " Adverse events were generally mild and transient." | 2.76 | Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis. ( Block, SL; Hamed, K; Waldmeier, F; Yogev, R, 2011) |
| "To assess time to next recurrence and development of antiviral resistance in patients with recurrent genital herpes treated with either single-day famciclovir (1 g twice-daily) or 3-day valacyclovir (500 mg twice-daily)." | 2.74 | Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance. ( Abudalu, M; Bodsworth, N; Fife, K; Hamed, K; Koltun, W; Prichard, M; Tyring, S, 2009) |
| " Although traditional therapy for a recurrent episode for healthy adults has consisted of twice-daily dosing for 5 days, recent studies have indicated that shorter courses of antiviral therapy are effective." | 2.72 | Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. ( Aoki, FY; Diaz-Mitoma, F; Gao, J; Gross, G; Hamed, K; Tyring, S, 2006) |
| "Genital herpes is a lifelong incurable viral infection that can have a significant psychological and emotional impact on patients." | 2.72 | Single-day famciclovir therapy for recurrent genital herpes. ( Diaz-Mitoma, F; Hamed, K; Whitley, R, 2006) |
| "In immunocompetent adults with recurrent genital herpes, a 5-day course of famciclovir at a dosage of 125 mg, 250 mg, or 500 mg twice per day was significantly more effective than was placebo in reducing the duration of viral shedding and symptoms and in accelerating lesion healing." | 2.71 | Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial. ( Aoki, FY; Lassonde, M; Martel, AY; Sacks, SL; Shafran, SD, 2005) |
| "Recurrent genital herpes simplex virus (HSV) may be treated episodically, but this may not be sufficient for patients with frequent recurrences." | 2.69 | Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. ( Boon, R; Diaz-Mitoma, F; Saltzman, RL; Shafran, SD; Sibbald, RG, 1998) |
| "No HSV recurrences were seen in 90% of patients receiving famciclovir at either dose." | 2.69 | Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. ( Alster, TS; Nanni, CA, 1999) |
| "The median time to first recurrence was 82 days in the placebo group, 114 days in those receiving famciclovir, 125 mg once daily, and more than 120 days in the other treatment groups." | 2.68 | Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group. ( Fowler, SL; Goade, D; Kraus, SJ; Levin, MJ; Loveless, MO; Mertz, GJ; Tyring, SK, 1997) |
| " Famciclovir has received single-day dosing indications for both of these entities." | 2.44 | Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications. ( Chacko, M; Weinberg, JM, 2007) |
| " Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections." | 2.44 | The treatment of herpes simplex infections: an evidence-based review. ( Brodell, RT; Cernik, C; Gallina, K, 2008) |
| "One common method for treating recurrent genital herpes outbreaks is 3-5 day episodic therapy with nucleoside analogues." | 2.44 | Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes. ( Hamed, K; Richwald, G; Tyring, S, 2007) |
| " Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes." | 2.43 | Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. ( Lyseng-Williamson, KA; Simpson, D, 2006) |
| "Future possibilities for treatment of genital herpes include a microparticle-based controlled-release formulation of aciclovir and resiquimod (VML-600; R-848)." | 2.41 | Current recommendations for the treatment of genital herpes. ( Leung, DT; Sacks, SL, 2000) |
| "Lamivudine was effective also after famciclovir breakthrough in 94% of patients." | 1.31 | [Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases]. ( Bechstein, WO; Berg, T; Hopf, U; Langrehr, JM; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Platz, KP; Rayes, N; Seehofer, D; Steinmüller, T, 2000) |
| "In contrast only 18% developed HBV recurrence under perioperative lamivudine treatment." | 1.31 | Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. ( Bechstein, WO; Berg, T; Müller, AR; Naumann, U; Neuhaus, P; Neuhaus, R; Rayes, N; Seehofer, D; Steinmüller, T; Tullius, SG, 2001) |
| "We have documented HBV recurrence in a liver transplant recipient with the emergence of a multidrug resistant HBV which caused graft loss." | 1.30 | The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. ( Bartholomeusz, AI; de Man, RA; Locarnini, SA; Niesters, HG; Zondervan, PE, 1998) |
| "Famciclovir is a useful agent in the treatment of hepatitis B in the liver transplant recipient." | 1.30 | Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir. ( Busuttil, RW; Han, SH; Hiserodt, D; Holt, C; Imagawa, D; Kinkhabwala, M; Martin, P; Murray, N; Rudich, S; Seu, P, 1998) |
| " Its bioavailability means that it can be taken less frequently than acyclovir, the only other approved herpes treatment." | 1.29 | Drug effective against herpes. ( , 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 27 (39.71) | 18.2507 |
| 2000's | 35 (51.47) | 29.6817 |
| 2010's | 6 (8.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le Cleach, L | 1 |
| Trinquart, L | 1 |
| Do, G | 1 |
| Maruani, A | 1 |
| Lebrun-Vignes, B | 2 |
| Ravaud, P | 1 |
| Chosidow, O | 4 |
| Routt, E | 1 |
| Levitt, J | 1 |
| Arain, N | 1 |
| Paravastu, SC | 1 |
| Arain, MA | 1 |
| Ise, M | 1 |
| Tanese, K | 1 |
| Adachi, T | 1 |
| Du, W | 1 |
| Amagai, M | 1 |
| Ohyama, M | 1 |
| Cernik, C | 1 |
| Gallina, K | 1 |
| Brodell, RT | 1 |
| Abudalu, M | 3 |
| Tyring, S | 5 |
| Koltun, W | 2 |
| Bodsworth, N | 2 |
| Hamed, K | 8 |
| Fife, K | 1 |
| Prichard, M | 1 |
| Leone, P | 1 |
| Mitha, E | 1 |
| Gani, M | 1 |
| Zhou, W | 1 |
| Block, SL | 1 |
| Yogev, R | 1 |
| Waldmeier, F | 1 |
| Lim, SG | 1 |
| Wai, CT | 1 |
| Rajnakova, A | 1 |
| Kajiji, T | 1 |
| Guan, R | 1 |
| Fischer, L | 2 |
| Sterneck, M | 2 |
| Meier, D | 1 |
| Zöllner, B | 2 |
| Rogiers, X | 2 |
| Terrault, NA | 1 |
| Raborn, GW | 2 |
| Grace, MG | 1 |
| Chan, KS | 1 |
| Grace, M | 1 |
| Jensen, LA | 1 |
| Hoehns, JD | 1 |
| Squires, CL | 1 |
| Sacks, SL | 5 |
| Aoki, FY | 5 |
| Martel, AY | 1 |
| Shafran, SD | 3 |
| Lassonde, M | 1 |
| Diaz-Mitoma, F | 6 |
| Gross, G | 1 |
| Gao, J | 1 |
| Wald, A | 1 |
| Selke, S | 1 |
| Warren, T | 1 |
| Sacks, S | 2 |
| Corey, L | 1 |
| Whitley, R | 1 |
| Berger, T | 1 |
| Yen-Moore, A | 1 |
| Tharp, M | 1 |
| Richwald, G | 1 |
| Shalabi, M | 1 |
| Whitley, RJ | 1 |
| Simpson, D | 1 |
| Lyseng-Williamson, KA | 1 |
| Bouzamondo, A | 1 |
| Dupuy, A | 1 |
| Guillaume, JC | 1 |
| Lechat, P | 1 |
| Chacko, M | 1 |
| Weinberg, JM | 1 |
| Sellors, J | 1 |
| Ruben, M | 1 |
| MacPherson, P | 1 |
| Caissie, G | 1 |
| Brown, D | 2 |
| Haller, GW | 1 |
| Bechstein, WO | 5 |
| Neuhaus, R | 5 |
| Raakow, R | 1 |
| Berg, T | 5 |
| Hopf, U | 2 |
| Neuhaus, P | 5 |
| Mertz, GJ | 1 |
| Loveless, MO | 1 |
| Levin, MJ | 1 |
| Kraus, SJ | 1 |
| Fowler, SL | 1 |
| Goade, D | 1 |
| Tyring, SK | 1 |
| Krüger, M | 1 |
| Tillmann, HL | 2 |
| Trautwein, C | 2 |
| Bode, U | 1 |
| Oldhafer, K | 2 |
| Maschek, H | 1 |
| Böker, KH | 2 |
| Broelsch, CE | 1 |
| Pichlmayr, R | 1 |
| Manns, MP | 2 |
| Scoular, A | 1 |
| Barton, S | 1 |
| Yoshida, EM | 1 |
| Ma, MM | 1 |
| Davis, JE | 1 |
| Fischer, KP | 1 |
| Kneteman, NM | 1 |
| Erb, SR | 1 |
| Tyrrell, DL | 1 |
| Bain, VG | 1 |
| Golling, M | 1 |
| Arnold, JC | 1 |
| Rudek, B | 1 |
| Theilmann, L | 1 |
| Herfarth, C | 1 |
| Otto, G | 1 |
| Sibbald, RG | 1 |
| Boon, R | 1 |
| Saltzman, RL | 1 |
| Angel, S | 1 |
| Boineau-Géniaux, D | 1 |
| Salag, P | 1 |
| Trepsat, F | 1 |
| Perrot, JL | 1 |
| Will, F | 1 |
| Grognard, C | 1 |
| Livir-Rallatos, C | 1 |
| El-Shabrawi, Y | 1 |
| Zatirakis, P | 1 |
| Pellett, PE | 1 |
| Stamey, FR | 1 |
| Foster, CS | 1 |
| Han, SH | 1 |
| Kinkhabwala, M | 1 |
| Martin, P | 1 |
| Holt, C | 1 |
| Murray, N | 1 |
| Seu, P | 1 |
| Rudich, S | 1 |
| Hiserodt, D | 1 |
| Imagawa, D | 1 |
| Busuttil, RW | 1 |
| de Man, RA | 1 |
| Bartholomeusz, AI | 1 |
| Niesters, HG | 1 |
| Zondervan, PE | 1 |
| Locarnini, SA | 1 |
| Alster, TS | 1 |
| Nanni, CA | 1 |
| Bock, T | 1 |
| Jäckel, E | 1 |
| Glowienka, M | 1 |
| Bruns, I | 1 |
| Gauthier, J | 1 |
| Condreay, LD | 1 |
| Raab, HR | 1 |
| Ritzmann, P | 1 |
| Young, CL | 1 |
| Thackray, AM | 2 |
| Field, HJ | 2 |
| Volpi, A | 1 |
| Testore, GP | 1 |
| Sarrecchia, C | 1 |
| Rayes, N | 4 |
| Seehofer, D | 4 |
| Müller, AR | 4 |
| Wall, SH | 1 |
| Ramey, SJ | 1 |
| Wall, F | 1 |
| Geers, TA | 1 |
| Isada, CM | 1 |
| Drake, S | 1 |
| Taylor, S | 1 |
| Pillay, D | 1 |
| Naumann, U | 2 |
| Langrehr, JM | 1 |
| Steinmüller, T | 2 |
| Platz, KP | 1 |
| Leung, DT | 1 |
| Berenguer, M | 1 |
| Prieto, M | 1 |
| Rayón, M | 1 |
| Bustamante, M | 1 |
| Carrasco, D | 1 |
| Moya, A | 1 |
| Pastor, MA | 1 |
| Gobernado, M | 1 |
| Mir, J | 1 |
| Berenguer, J | 1 |
| Drouault, Y | 1 |
| Leconte-Veyriac, F | 1 |
| Aymard, M | 1 |
| Ortonne, JP | 1 |
| Pouget, F | 1 |
| Revuz, J | 1 |
| Decazes, JM | 1 |
| Malkin, JE | 1 |
| Cahlin, C | 1 |
| Olausson, M | 1 |
| Friman, S | 1 |
| Tullius, SG | 1 |
| Sohn, S | 1 |
| Bang, D | 1 |
| Lee, ES | 1 |
| Kwon, HJ | 1 |
| Lee, SI | 1 |
| Lee, S | 1 |
| Yuan, G | 1 |
| Duan, Y | 1 |
| Wang, F | 1 |
| Liang, S | 1 |
| Zhu, L | 1 |
| Stanberry, LR | 1 |
| Rosenthal, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Patient-initiated Famciclovir 1000 mg b.i.d. x 1 Day to Valacyclovir 500 mg b.i.d. x 3 Days in Immunocompetent Adults With Recurrent Genital Herpes[NCT00306787] | Phase 3 | 1,179 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| A Randomized, Multicenter, Double-blind Study to Compare the Efficacy of Single-day Treatment (1000 mg b.i.d.) With Famciclovir Compared to That of Placebo in Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Immunocompetent Black Patien[NCT00477334] | Phase 4 | 463 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis[NCT00878072] | Phase 2/Phase 3 | 53 participants (Actual) | Interventional | 2009-03-25 | Completed | ||
| A Randomized, Efficacy Assessor-Blinded, Study to Assess Preliminary Efficacy and Safety of EDTA Eye Drops v. an Active Comparator in the Suppression of Herpes Simplex Virus Eruptions in Subjects With a History of Herpes Labialis[NCT04893577] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-01-20 | Enrolling by invitation | ||
| Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women[NCT02053142] | 74 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lesions that developed no further than the papule stage (erythema may have been present) were considered as aborted lesions. Prodrome also was considered the sign of aborted lesions in this study. Lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing were considered as non-aborted lesions. The median time was estimated using Kaplan-Meier method. (NCT00306787)
Timeframe: 72 hours after initiation of study medication up to Day 20
| Intervention | days (Median) |
|---|---|
| Famciclovir | 3.07 |
| Valacyclovir | 3.01 |
Time to healing of all non-aborted genital herpes lesions was defined as the time from the first dose of study drug taken no earlier than the recurrence of genital herpes to the investigator-assessed time of healing (i.e. loss of all crusts and re-epithelialization of the lesions; erythema could have been present). Non-aborted lesions are lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing. The median time was estimated using Kaplan-Meier method by censoring missing values at the time of last clinical lesion observation. (NCT00306787)
Timeframe: 72 hours after initiation of study medication up to Day 20
| Intervention | days (Median) |
|---|---|
| Famciclovir | 4.25 |
| Valacyclovir | 4.08 |
Patients who experienced a first recurrence of genital herpes and took study medication were followed for a period of up to 6 months to the second recurrence. (NCT00306787)
Timeframe: Up to 6 months after investigator assessed healing of first recurrence of genital herpes
| Intervention | participants (Number) | |
|---|---|---|
| Patients continued in follow up period | Patients with 2nd recurrence in follow up period | |
| Famciclovir | 324 | 226 |
| Valacyclovir | 342 | 231 |
Lesions that developed no further than the papule stage (erythema may have been present) were considered as aborted lesions. Prodrome also was considered the sign of aborted lesions in this study. Lesions which underwent vesicle, ulcer/soft crust, and/or hard crust formation and required re-epithelialization for healing were considered as non-aborted lesions. (NCT00306787)
Timeframe: 72 hours after initiation of study medication up to Day 20
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Aborted Lesions | Non-Aborted lesions | |
| Famciclovir | 32.7 | 67.3 |
| Valacyclovir | 33.6 | 66.4 |
"Patients who experienced a first recurrence of genital herpes and took study medication were followed for a period of up to 6 months to the second recurrence. Time to a second recurrence of genital herpes was calculated in 2 ways as follows:~From the date of treatment initiation no earlier than the recurrence of genital herpes to the date of onset for the second recurrence, or~From the date of healing of non-aborted lesions or confirmation of aborted lesions to the date of onset for the second recurrence." (NCT00306787)
Timeframe: Up to 6 months after investigator assessed healing of first recurrence of genital herpes
| Intervention | days (Median) | |
|---|---|---|
| From treatment initiation | From date of healing /confirmation | |
| Famciclovir | 33.5 | 27.5 |
| Valacyclovir | 38.0 | 32.0 |
Kaplan-Meier estimated time in hours of the resolution of all symptoms (pain, burning, itching, tingling and tenderness) associated with recurrent genital herpes. Kaplan-Meier method is used to estimate the time to resolution of symptoms. (NCT00306787)
Timeframe: 72 hours after initiation of study medication up to Day 20
| Intervention | hours (Median) | ||||
|---|---|---|---|---|---|
| Pain (n = 220, 228) | Burning (n = 221, 218) | Itching (n = 309, 297) | Tingling (n = 266, 275) | Tenderness (n = 298, 311) | |
| Famciclovir | 18.0 | 16.1 | 43.9 | 23.8 | 55.2 |
| Valacyclovir | 20.3 | 12.6 | 43.5 | 23.0 | 48.0 |
Kaplan-Meier estimation. (NCT00477334)
Timeframe: 21 days
| Intervention | Days (Median) |
|---|---|
| Famciclovir 1000 mg | 4.13 |
| Placebo Comparator | 4.06 |
Time to healing of all non-aborted genital herpes lesions, defined as the time from the first dose of study medication to the investigator-assessed time of healing (i.e. loss of all crusts and re-epithelialization of lesions; erythema may be present). (NCT00477334)
Timeframe: 21 days
| Intervention | Days (Median) |
|---|---|
| Famciclovir 1000 mg | 5.38 |
| Placebo Comparator | 4.79 |
Number of participants with a second recurrence of genital herpes in the follow-up period. (NCT00477334)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Famciclovir 1000 mg | 141 |
| Placebo Comparator | 75 |
(NCT00477334)
Timeframe: 21 days
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| Percentage with aborted lesions (n=49,20) | Percentage with non-aborted lesions (n= 152,78) | |
| Famciclovir 1000 mg | 24.4 | 75.6 |
| Placebo Comparator | 20.4 | 79.6 |
"The number of participants with clinically noted shifts in Clinical Chemistry tests from normal at baseline are graded based on Division of Microbiology and Infectious Diseases (DMID) toxicity tables from Grade 1 toxicity (smallest change) to Grade 4 toxicity (largest change). Grade 3 and 4 toxicities are considered to be clinically meaningful.~SGPT(ALT)= Serum Glutamic Pyruvate Transaminase (Alanine Aminotransferase) and SGOT(AST)= Serum Glutamic Oxalacetic Transaminase (Aspartate Aminotransferase)" (NCT00477334)
Timeframe: Baseline, Day 2
| Intervention | Participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SGPT(ALT)-Famciclovir (n=183) | SGPT(ALT)-Placebo (n=92) | SGOT(AST)-Famciclovir (n=190) | SGOT(AST)-Placebo (n=92) | Blood Urea Nitrogen-Famciclovir (n=196) | Blood Urea Nitrogen-Placebo (n=95) | Creatinine-Famciclovir (n=182) | Creatinine-Placebo (n=90) | Bilirubin(total)-Famciclovir (n=192) | Bilirubin(total)-Placebo (n=93) | Amylase-Famciclovir (n=152) | Amylase-Placebo (n=72) | Lipase-Famciclovir (n=190) | Lipase-Placebo (n=90) | |
| Grade 1 Toxicity | 3 | 1 | 4 | 0 | 0 | 0 | 16 | 5 | 1 | 1 | 6 | 3 | 2 | 1 |
| Grade 2 Toxicity | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 1 |
| Grade 3 Toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 4 Toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of participants with clinically noted shifts in Hematology tests from normal at baseline are graded based on Division of Microbiology and Infectious Diseases (DMID) toxicity tables from Grade 1 toxicity (smallest change) to Grade 4 toxicity (largest change). Grade 3 and 4 toxicities are considered to be clinically meaningful. (NCT00477334)
Timeframe: Baseline, Day 2
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Haematocrit-Famciclovir (n=186) | Haematocrit-Placebo (n=87) | Haemoglobin-Famciclovir (n=183) | Haemoglobin-Placebo(n=88) | Absolute Neutrophils-Famciclovir (n=177) | Absolute Neutrophils-Placebo (n=83) | WBC(total)-Famciclovir (n=163) | WBC(total)-Placebo(n=98) | Platelet count-Famciclovir (n=184) | Platelet count-Placebo (n=88) | |
| Grade 1 Toxicity | 0 | 0 | 2 | 3 | 6 | 0 | 15 | 6 | 0 | 0 |
| Grade 2 Toxicity | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 0 |
| Grade 3 Toxicity | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Grade 4 Toxicity | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Median time to resolution of symptoms: all symptoms, pain, burning, itching, tingling and tenderness associated with recurrent genital herpes estimated using Kaplan-Meier method. (NCT00477334)
Timeframe: 72 hour after initiation of study medication up to 21 days
| Intervention | Days (Median) | |||||
|---|---|---|---|---|---|---|
| All symptoms (n=195/98) | Pain (n=141,69) | Burning (n=126,65) | Itching (n=168,86) | Tingling (n=141,70) | Tenderness (n=147/74) | |
| Famciclovir 1000 mg | 4.5 | 3.0 | 2.3 | 3.2 | 2.0 | 3.4 |
| Placebo Comparator | 5.7 | 2.6 | 2.5 | 3.5 | 2.3 | 2.9 |
Kaplan Meier estimated time in days to second recurrent from treatment initiation and from the date of healing of aborted lesions. (NCT00477334)
Timeframe: 6 months
| Intervention | Days (Median) | |
|---|---|---|
| Time from initiation of treatment | Time from healing of non-aborted lesion | |
| Famciclovir 1000 mg | 69.0 | 63.0 |
| Placebo Comparator | 81.0 | 75.0 |
CL/F was defined as the apparent oral clearance of penciclovir from plasma = dose of famciclovir*0.7884/AUC 0-inf, where 0.7884 is the ratio of the molecular weight of penciclovir (253.3 g/mol) to famciclovir (321.3 g/mol). F is the bioavailability of penciclovir after oral administration of famciclovir. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using LC/MS/MS method. The limit of quantification was 0.15 µg/mL for both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Litres(L)/Hour(h) (Mean) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 38.2 |
T½ was defined as the apparent terminal elimination half-life= ln 2/ λz. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using LC/MS/MS method. The limit of quantification was 0.15 µg/mL For both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Hours (Mean) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 1.81 |
| 6-Deoxy Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 0.78 |
AUC 0-tlast was defined as the area under the plasma concentration-time curve from time zero up to the last quantifiable concentration (Clast) calculated by the linear trapezoidal rule. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using LC/MS/MS method. The limit of quantification was 0.15 µg/mL for both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Microgram(µg)/Milliliter(mL)*Hour(h) (Mean) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 30.80 |
| 6-Deoxy Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 5.42 |
AUC 0-infinity was defined as the area under the plasma concentration time curve from time zero to infinity = AUC 0-tlast + C last /λ z, where λz is the apparent elimination rate constant estimated by linear regression analysis of the terminal portion of the log-linear plasma concentration-time curve. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using LC/MS/MS method. The limit of quantification was 0.15 µg/mL for both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Microgram(µg)/Milliliter(mL)*Hour(h) (Mean) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 31.76 |
| 6-Deoxy Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 6.61 |
Cmax was defined as the maximum observed plasma concentration. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using LC/MS/MS method. The limit of quantification was 0.15 µg/mL for both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Microgram (µg)/milliliter(mL) (Mean) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 9.37 |
| 6-Deoxy Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 3.32 |
Tmax was defined as the time to reach maximum plasma concentration. Penciclovir (active metabolite from famciclovir) and 6-deoxypenciclovir (first intermediate metabolite from famciclovir) were determined by using a validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) method. The limit of quantification was 0.15 microgram (µg)/milliliter (mL) for both compounds. Calculations were done in WinNonlin 5.0.1, using non-compartmental methods. (NCT00878072)
Timeframe: Pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6 and 10 hours Post-dose
| Intervention | Hours (Median) |
|---|---|
| Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 1 |
| 6-Deoxy Penciclovir (Participants Aged 12 to Less Than [<] 18 Years) | 1 |
AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. (NCT00878072)
Timeframe: From Start of the Study up to Day 36
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Famciclovir (Participants Aged 12 to Less Than [<] 15 Years) | 6 | 0 |
| Famciclovir (Participants Aged 15 to Less Than [<] 18 Years) | 6 | 0 |
Participants with laboratory values outside the defined normal range were graded as clinically significant laboratory abnormalities. Laboratory values were assessed according to the National Cancer Institute- Common terminology criteria for Adverse Events (NCI-CTCAE). Hematology, Urinalysis and clinical chemistry were reported . (NCT00878072)
Timeframe: From Start of the Study up to Day 36
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematology | Clinical chemistry | Urinalysis | |
| Famciclovir (Participants Aged 12 to Less Than [<] 15 Years) | 0 | 0 | 0 |
| Famciclovir (Participants Aged 15 to Less Than [<] 18 Years) | 0 | 0 | 0 |
17 reviews available for brl 42810 and Recrudescence
| Article | Year |
|---|---|
Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Adult; Antiviral Agents; Famciclovir; Female; Herpes | 2014 |
Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis.
Topics: 2-Aminopurine; Acyclovir; Administration, Cutaneous; Administration, Oral; Adrenal Cortex Hormones; | 2015 |
The treatment of herpes simplex infections: an evidence-based review.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Drug Resistance, Viral; Evidence-Based Medicine; Famcicl | 2008 |
Recurrent herpes simplex labialis: selected therapeutic options.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Administration, Topical; Adult; Antiviral Agents; Ch | 2003 |
Oral antivirals for the acute treatment of recurrent herpes labialis.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Clinical Trials as Topic; Famciclo | 2004 |
Single-day therapy for recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Dose-Response Relationship, Drug; Famciclovir; Herpes Genitalis; Hu | 2006 |
Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Drug Administration Schedule; Famciclovir; Herpes Genitalis; Humans | 2007 |
Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Famciclovir; Herpes Genitalis; Herpes Labialis; Herpes Zos | 2006 |
A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Disease Outbreaks; Drug Administra | 2007 |
Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications.
Topics: 2-Aminopurine; Administration, Oral; Antiviral Agents; Drug Administration Schedule; Famciclovir; He | 2007 |
The continuing evolution of antiviral therapy for recurrent genital herpes: 1-day patient-initiated treatment with famciclovir.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans | 2007 |
Use of penciclovir and famciclovir in the management of genital herpes.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Guanine; Herpes Genitalis; Humans; Recurren | 1996 |
Genital herpes simplex virus and its treatment: focus on famciclovir.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Herpes Genitalis; Humans; Recurrence | 1996 |
Famciclovir update. Chronic hepatitis B.
Topics: 2-Aminopurine; Antiviral Agents; Clinical Trials, Phase II as Topic; Famciclovir; Hepatitis B, Chron | 1999 |
Improving the care of patients with genital herpes.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Cesarean Section; Drug Administration Schedule; F | 2000 |
Current recommendations for the treatment of genital herpes.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Famciclovir; Female; Herpes | 2000 |
Genital herpes simplex virus infection in the adolescent: special considerations for management.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Antiviral Agents; Complementary Therapies; Famciclovir; Female | 2002 |
21 trials available for brl 42810 and Recrudescence
| Article | Year |
|---|---|
Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind | 2008 |
Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance.
Topics: 2-Aminopurine; Antiviral Agents; Drug Resistance, Viral; Famciclovir; Herpes Genitalis; Humans; Recu | 2009 |
One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Antiviral Agents; Black People; Double-Blind Method; Famcicl | 2010 |
Safety and pharmacokinetics of a single 1500-mg dose of famciclovir in adolescents with recurrent herpes labialis.
Topics: 2-Aminopurine; Adolescent; Antiviral Agents; Child; Famciclovir; Female; Herpes Labialis; Humans; Ma | 2011 |
Clinic-initiated, twice-daily oral famciclovir for treatment of recurrent genital herpes: a randomized, double-blind, controlled trial.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; | 2005 |
Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Fa | 2006 |
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule | 2006 |
Single-day famciclovir therapy for recurrent genital herpes.
Topics: 2-Aminopurine; Administration, Oral; Antiviral Agents; Famciclovir; Herpes Genitalis; Humans; Recurr | 2006 |
Single-day therapy for recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Dose-Response Relationship, Drug; Famciclovir; Herpes Genitalis; Hu | 2006 |
Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes. A randomized, double-blind multicenter trial. Canadian Famciclovir Study Group.
Topics: 2-Aminopurine; Administration, Oral; Adult; Antiviral Agents; Double-Blind Method; Drug Administrati | 1996 |
Detection of viral DNA to evaluate outcome of antiviral treatment of patients with recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Herpes Genitalis; Humans; Polymerase Chain | 1996 |
Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Adult; Antigen-Antibody Complex; Antiviral Agents; D | 1997 |
Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; DNA, Viral; Famciclovir; Female; | 1996 |
Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group.
Topics: 2-Aminopurine; Administration, Oral; Adult; Aged; Antiviral Agents; Double-Blind Method; Famciclovir | 1998 |
Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Facial Dermatoses; Famciclovir; Female; Herpes Simplex | 1999 |
[Expensive long-term care with virustatic drugs frequently reduces herpes genitalis episodes].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Famc | 1999 |
Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Famciclovir; Female; Hepatitis B; Humans; Liver Transplantat | 1999 |
Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial.
Topics: 2-Aminopurine; Acyclovir; Adult; Aged; Aged, 80 and over; Antiviral Agents; Double-Blind Method; Fam | 2001 |
Famciclovir effective in suppressing recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Double-Blind Method; Famciclovir; Herpes Genitalis; Humans; Recurre | 1996 |
Famvir effective in suppressing recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Double-Blind Method; Famciclovir; Female; Herpes Simplex; Humans; M | 1998 |
[Prevention and treatment of HBV reinfection following liver transplantation].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Biopsy; DNA, Viral; Drug Combinations; Famciclovir; Female; | 2002 |
31 other studies available for brl 42810 and Recrudescence
| Article | Year |
|---|---|
Famciclovir for recurrent herpes-associated erythema multiforme: a series of three cases.
Topics: 2-Aminopurine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dr | 2014 |
Postherpetic Wolf's isotopic response: possible contribution of resident memory T cells to the pathogenesis of lichenoid reaction.
Topics: 2-Aminopurine; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antiviral Agents; Famciclovir; | 2015 |
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B.
Topics: 2-Aminopurine; Adult; Aged; Alanine Transaminase; Antiviral Agents; Bilirubin; DNA, Viral; Drug Resi | 2002 |
The use of antiviral monotherapy and combination therapy for patients with hepatitis B virus infection after liver transplantation.
Topics: 2-Aminopurine; Antiviral Agents; Drug Therapy, Combination; Famciclovir; Hepatitis B; Hepatitis B Su | 2002 |
Treatment of recurrent hepatitis B infection in liver transplant recipients.
Topics: 2-Aminopurine; Adenine; Antiviral Agents; Famciclovir; Hepatitis B; Humans; Interferon-alpha; Lamivu | 2002 |
Treatment modalities and medication recommended by health care professionals for treating recurrent herpes labialis.
Topics: 2-Aminopurine; Acyclovir; Alberta; Antiviral Agents; Attitude of Health Personnel; Dentists; Drug Co | 2004 |
Recurrent benign lymphocytic meningitis.
Topics: 2-Aminopurine; Acyclovir; Adult; Aged; Antiviral Agents; Famciclovir; Female; Herpesvirus 2, Human; | 2006 |
Oral famciclovir for recurrent genital herpes.
Topics: 2-Aminopurine; Acute Disease; Adult; Antiviral Agents; Double-Blind Method; Famciclovir; Herpes Geni | 1996 |
Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation.
Topics: 2-Aminopurine; Antiviral Agents; DNA, Viral; Famciclovir; Hepatitis B; Humans; Liver Transplantation | 1996 |
Therapy for genital herpes in immunocompromised patients: a national survey. The Herpes Simplex Advisory Panel.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Resistance, | 1997 |
Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Drug Resistance, Microbial; Famciclovir; Female; Follow-Up S | 1998 |
[Prevention of hepatitis B--analysis of cost-effectiveness after liver transplantation].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Cost-Benefit Analysis; Famciclovir; Female; Hepatitis B; Hum | 1997 |
[Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area].
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chemexfoliation; Chemoprevention; Dermabrasion; Dermatit | 1998 |
Recurrent nodular scleritis associated with varicella zoster virus.
Topics: 2-Aminopurine; Antigens, Viral; Antiviral Agents; DNA Primers; DNA, Viral; Famciclovir; Female; Fluo | 1998 |
Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Female; Hepatitis B; Humans; Liver Transplantation; Mi | 1998 |
The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.
Topics: 2-Aminopurine; Amino Acid Sequence; Antiviral Agents; DNA-Directed DNA Polymerase; DNA, Viral; Drug | 1998 |
Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.
Topics: 2-Aminopurine; Adult; Amino Acid Substitution; Antiviral Agents; DNA Primers; DNA-Directed DNA Polym | 1999 |
Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Brain Stem; Ear; Famciclovir; Female; Herpes Ge | 2000 |
[Herpes genitalis].
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Famciclovir; Female; Herpes Genitalis; Humans; Ma | 1999 |
Famciclovir as antiviral prophylaxis in laser resurfacing procedures.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; D | 1999 |
Effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice: how dissimilar are study results?
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Disease Models, Animal; Famciclovir; Herpes Sim | 2000 |
Update on antiviral therapy for genital herpes infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Female; Herpes Genitalis; Herpes Simplex; H | 2000 |
[Therapy of recurrent hepatitis B infection after liver transplantation. A retrospective analysis of 200 liver transplantations based on hepatitis B associated liver diseases].
Topics: 2-Aminopurine; Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedu | 2000 |
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; DNA, Viral; Drug Resistance, Microbial; Drug | 2000 |
Lamivudine improves the prognosis of patients with hepatitis B after liver transplantation.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Follow-Up Studies; Hepatitis B; Humans; Lamivudine; Li | 2000 |
Famciclovir treatment in transplant recipients with HBV-related liver disease: disappointing results.
Topics: 2-Aminopurine; Adult; Alanine Transaminase; Antiviral Agents; DNA, Viral; Famciclovir; Female; Follo | 2001 |
Drug effective against herpes.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Famciclovir; Herpes Genitalis; Humans; Recurre | 1996 |
Herpes drug suppresses HSV in people with HIV.
Topics: 2-Aminopurine; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Famciclovir; Female; Herpes Ge | 1999 |
Severe clinical course of de novo hepatitis B infection after liver transplantation.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Famciclovir; Fatal Outcome; Female; Hepatitis B; Humans; Lam | 2001 |
Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation.
Topics: 2-Aminopurine; Adult; Antiviral Agents; DNA, Viral; Famciclovir; Female; Hepatitis B; Humans; Immuno | 2001 |
Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Behcet Syndrome; Disease Models, Animal; Famciclovir; Herp | 2001 |